|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.4889 USD | +1.88% |
|
+7.24% | -59.26% |
| Apr. 02 | Centogene Gets Nasdaq Noncompliance Notice | MT |
| Mar. 19 | Centogene, Takeda Pharmaceutical Collaborate on Lysosomal Storage Disorders Diagnostics | MT |
Centogene N.V. reported earnings results for the half year ended June 30, 2023. For the half year, the company reported sales was EUR 24.62 million compared to EUR 21.39 million a year ago. Net loss was EUR 24.46 million compared to EUR 16.93 million a year ago.
Basic loss per share from continuing operations was EUR 0.88 compared to EUR 0.88 a year ago. Basic loss per share was EUR 0.88 compared to EUR 0.64 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -59.26% | 13.62M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
CENTOGENE N.V. 
